NO942660L - Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier - Google Patents

Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier

Info

Publication number
NO942660L
NO942660L NO942660A NO942660A NO942660L NO 942660 L NO942660 L NO 942660L NO 942660 A NO942660 A NO 942660A NO 942660 A NO942660 A NO 942660A NO 942660 L NO942660 L NO 942660L
Authority
NO
Norway
Prior art keywords
cells
cytolytic
precursors
pbmcs
characteristic
Prior art date
Application number
NO942660A
Other languages
English (en)
Norwegian (no)
Other versions
NO942660D0 (no
Inventor
Pierre G Coulie
Thierry Boon
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NO942660D0 publication Critical patent/NO942660D0/no
Publication of NO942660L publication Critical patent/NO942660L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
NO942660A 1992-01-21 1994-07-15 Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier NO942660L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82393392A 1992-01-21 1992-01-21
PCT/US1993/000083 WO1993014189A1 (en) 1992-01-21 1993-01-07 Method for determining cytolytic t cell precursors

Publications (2)

Publication Number Publication Date
NO942660D0 NO942660D0 (no) 1994-07-15
NO942660L true NO942660L (no) 1994-09-16

Family

ID=25240169

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942660A NO942660L (no) 1992-01-21 1994-07-15 Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier

Country Status (8)

Country Link
EP (1) EP0624189A4 (fi)
JP (1) JPH07503134A (fi)
KR (1) KR950700402A (fi)
AU (1) AU3435293A (fi)
CA (1) CA2128424A1 (fi)
FI (1) FI943422A0 (fi)
NO (1) NO942660L (fi)
WO (1) WO1993014189A1 (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100261856B1 (ko) * 1991-05-23 2000-07-15 에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 종양 거부 항원 전구체, 종양 거부 항원 및 그 용도
US6352826B1 (en) 1991-11-25 2002-03-05 Yoreh Biotechnologies, Ltd. Method and kit for the detection of retroviral specific antibodies in seronegative individuals
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2188432C (en) 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
AU1394497A (en) * 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
AU5066098A (en) * 1996-11-22 1998-06-10 Shiloov Medical Technologies Ltd. A whole blood/mitogen assay for the early detection of a subject with cancer and kit

Also Published As

Publication number Publication date
NO942660D0 (no) 1994-07-15
JPH07503134A (ja) 1995-04-06
EP0624189A4 (en) 1995-05-17
FI943422A (fi) 1994-07-19
KR950700402A (ko) 1995-01-16
EP0624189A1 (en) 1994-11-17
AU3435293A (en) 1993-08-03
FI943422A0 (fi) 1994-07-19
WO1993014189A1 (en) 1993-07-22
CA2128424A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
NO942660L (no) Fremgangsmåte til bestemmelse av cytolytiske T-celle-forstadier
DK122184D0 (da) Indretning til mikrobiologisk afproevning
DK393886A (da) Monoklone antistoffer og antigen for humane ikke-smaacellede lungecarcinomer
FI873398A (fi) Bestaemning av kliniska parametrar med hjaelp av en enzymatisk immunoprocess.
EP0140379A3 (en) Method and apparatus for measuring the degree of reaction between antigens and leukocyte cellular antibodies
ES511797A0 (es) "metodo para ensayar reacciones antigeno-anticuerpo".
NO932320L (no) Fremgangsmaate for paavisning av en analytt i en proeve og et utstyrsett for denne
DK199779A (da) Renset antigen til undersoegelse for neisseria gonorrhoeae antistoffer
DE2965570D1 (en) Method for the detection and/or determination of an antigen specific immunoglobulin, immuno-reagents to be used in said method and test kit for said determination
DK344579A (da) Diagnostisk middel og fremgangsmaade til paavisning af antimitochondriale eller antinukleaere antistoffer
NO168311C (no) Monoklonale antistoffer for humane ikke-smaacelle lungekarsinomer, cellelinjer som produserer disse samt diagnostisksett
NO961138L (no) Protein kinase C aktivatorer og anvendelse derav for å redusere ekspresjon av celleantigener
ES8706966A1 (es) Metodo de ensayar muestras de fluido en cuanto a la presencia de anticuerpos contra un microorganismo y dispositivo correspondiente
ATE135468T1 (de) Vorprüfung von prostatakrebs durch serum prostatischen spezifischen antigen
NO880835L (no) Fremgangsmaate og anordning for kvalitativ og/eller kvantitativ analyse av antigener, antistoffer, mikroorganismer eller andre celler.
ES2187639T3 (es) Analisis de fijacion competitiva para antigenos plaquetarios.
NO157358C (no) Antistoffreagens og fremgangsmaate for hurtig bestemmelse av tilstedevaerelse eller fravaer paa roede blodceller av d-antigen.
DK98692A (da) Monoklonalt antistof og fremgangsmaade til fremstilling deraf, hybridoma, som producerer det monoklonale antistof, og proeve for tumorcellefoelsomhed under anvendelse af det monoklonale antistof
SE7708625L (sv) Immunanalys for tymopoietin
DK112980A (da) Diagnosefremgangmaade og apparat til gennemfoerelse af fremgangsmaaden
JPS51144293A (en) Continuous analysis system of urine, etc
SE8603312D0 (sv) Sett att overvaka fermentering
CA2132868A1 (en) Method of using antibodies against human chorionic gonadotropin-related determinants to lyse, measure and enrich malignant cells
NO931613L (no) Fremgangsmaate for bestemming av sensiteten og/eller det spesifikke ved et proberingssystem for sporing av antistoffer
NO921879L (no) Fremgangsmaate til maaling av t-celleoverflateantigener i mennesker